Connor Clark & Lunn Investment Management Ltd. Has $15.62 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Sarepta Therapeutics by 66.2%, owning 244,769 shares worth approximately $15.6 million as of the latest report.
• Research analysts have mixed ratings for Sarepta Therapeutics, with a consensus rating of "Hold" and a price target averaging around $44.17, indicating cautious optimism.
• Sarepta Therapeutics posted a Q2 revenue of $611.09 million, significantly exceeding expectations, alongside an EPS of $2.02, demonstrating strong year-over-year growth.

Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 66.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 244,769 shares of the biotechnology company's stock after acquiring an additional 97,533 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.25% of Sarepta Therapeutics worth $15,621,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Byrne Asset Management LLC acquired a new stake in Sarepta Therapeutics during the 1st quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics during the first quarter valued at $31,000. UMB Bank n.a. raised its position in Sarepta Therapeutics by 53.0% during the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock valued at $51,000 after buying an additional 276 shares during the period. Logan Capital Management Inc. purchased a new stake in Sarepta Therapeutics in the 4th quarter worth about $61,000. Finally, Hurley Capital LLC boosted its position in Sarepta Therapeutics by 139.2% during the 1st quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company's stock worth $92,000 after acquiring an additional 835 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Up 4.8%

Shares of SRPT traded up $0.86 during trading hours on Tuesday, hitting $18.80. 7,536,464 shares of the company were exchanged, compared to its average volume of 23,381,442. The company has a market cap of $1.84 billion, a PE ratio of -21.61 and a beta of 0.46. The firm's 50 day moving average is $20.93 and its 200-day moving average is $55.53. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $144.22. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. The company had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. During the same quarter in the prior year, the company posted $0.07 EPS. The firm's revenue was up 68.4% on a year-over-year basis. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SRPT. Citigroup assumed coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They issued a "sell" rating on the stock. Wells Fargo & Company upped their price objective on shares of Sarepta Therapeutics from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, August 7th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Leerink Partners restated a "market perform" rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Finally, Baird R W downgraded shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 18th. Five research analysts have rated the stock with a sell rating, seventeen have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $44.17.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.